Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

There's plenty of misinformation out there, so we tapped doctors to explain the connection between cortisol levels and weight ...

Vertex bought the San Diego startup, projecting over $5 million in revenue per year for Crinetics developments.

A balanced cortisol keeps you alert, and your BP and sugar steady. Trouble starts when it rises and stays high for too long.

Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex's portfolio - PALSONIFY, Crinetics' recently launched, first ...

In a cohort of patients with difficult-to-control type 2 diabetes, more than 75% had elevated cortisol at a level that has ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Key Points Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better. Vertex Pharmaceuticals ...

First, let's take a look at Vertex's portfolio and general situation prior to the Crinetics move. As mentioned, the biotech is the global CF leader, specializing in CFTR modulators. These therapies ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.